Please assess the completion status of the following clinical trial:

Trial Title: Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥ 18 years)~* HIV-1 infection, clinical stability, and treatment with ATRIPLA ® for the past two years.~* Standard plasma viral load below the limit of detection for at least 2 years.~* CD4 count above 350/mm3 at the time of the consideration for the study.~* Negative pregnancy test in women of childbearing age, and commitment acceptable contraceptive use for at least 2 weeks before day 1 and until at least 6 months after the last dose of study drug.~* Patients should be given written informed consent~* In the opinion of the investigator, be able to follow the design of the protocol visits~Exclusion Criteria:~* Patients who have experienced virologic failure prior to any antiretroviral regimen~* Evidence of previous mutations versus efavirenz, tenofovir and emtricitabine~* Use of any other chronic treatment plus ATRIPLA has been introduced in the 6 months prior to entry of the patient in the study~* Any contraindication to study drug~* Any condition not ensure proper adherence to the study at the discretion of the attending physician of the patient~* Uncontrolled preexisting psychiatric illness~* Any current sign of alcoholism or other drug use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATRIPLA three times a week. (Type: EXPERIMENTAL): Atripla (600 mg/200 mg/245 mg) three times a week.
- ATRIPLA one time a day. (Type: ACTIVE_COMPARATOR): Atripla (600 mg/200 mg/245 mg) one time a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).